Abstract

Individuals suffering from severe viral respiratory tract infections have recently emerged as "at risk" groups for developing invasive fungal infections. Influenza virus is one of the most common causes of acute lower respiratory tract infections worldwide. Fungal infections complicating influenza pneumonia are associated with increased disease severity and mortality, with invasive pulmonary aspergillosis being the most common manifestation. Strikingly, similar observations have been made during the current coronavirus disease 2019 (COVID-19) pandemic. The copathogenesis of respiratory viral and fungal coinfections is complex and involves a dynamic interplay between the host immune defenses and the virulence of the microbes involved that often results in failure to return to homeostasis. In this review, we discuss the main mechanisms underlying susceptibility to invasive fungal disease following respiratory viral infections. A comprehensive understanding of these interactions will aid the development of therapeutic modalities against newly identified targets to prevent and treat these emerging coinfections.

MeSH

Coinfection, Respiratory Tract Infections, Microbiology, Covid-19, Influenza, Human, Viruses, Mycoses, Aspergillosis, Infections

Cited by

• Antifungal Activity of Biosynthesized Silver Nanoparticles (AgNPs) against Causing Aspergillosis: Ultrastructure Study. J Funct Biomater, 2022
• Cross-kingdom pathogen detection via duplex universal PCR and high-resolution melt. Biosens Bioelectron, 2024
• When disaster strikes fungi take control. Lancet Respir Med, 2022
• COVID-19 and Fungal infections: a double debacle. Microbes Infect, 2022
• Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis. J Fungi (Basel), 2022
• Clinical characteristics and severity prediction score of Adenovirus pneumonia in immunocompetent adult. PLoS One, 2023
• Pneumonia after Heart Transplantation: Two Case Reports and a Review of the Literature. Pathogens, 2023
• A Universal Aptamer for Influenza A Viruses: Selection, Recognition, and Infection Inhibition. ACS Pharmacol Transl Sci, 2024
• Association of COVID-19 risk factors with systemic fungal infections in hospitalized patients. medRxiv, 2024
• Differential Activation of Programmed Cell Death in Patients with Severe SARS-CoV-2 Infection. Res Sq, 2023
• Is neutropenia still the main risk factor for invasive aspergillosis? A contemporary university hospital retrospective cohort of invasive aspergillosis in neutropenic and non-neutropenic patients. Ann Clin Microbiol Antimicrob, 2025
• RNA SARS-CoV-2 Persistence in the Lung of Severe COVID-19 Patients: A Case Series of Autopsies. Front Microbiol, 2022
• Gut Microbial Disruption in Critically Ill Patients with COVID-19-Associated Pulmonary Aspergillosis. J Fungi (Basel), 2022
• Age difference of patients with and without invasive aspergillosis: a systematic review and meta-analysis. BMC Infect Dis, 2024
• COVID-19-associated pulmonary aspergillosis in mechanically ventilated patients: a prospective, multicentre UK study. Thorax, 2023
• Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field. J Fungi (Basel), 2022
• Role of liposomal amphotericin B in intensive care unit: an expert opinion paper. J Anesth Analg Crit Care, 2025
• Prevalence of COVID-19-Associated Pulmonary Aspergillosis: Critical Review and Conclusions. J Fungi (Basel), 2022
• Pathogenicity and virulence of Aspergillus fumigatus. Virulence, 2023
• Differential activation of programmed cell death in patients with severe SARS-CoV-2 infection. Cell Death Discov, 2023